Clinical Trial Update: To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CAN008 combined with re-irradiation for recurrent glioblastoma; results not yet specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CAN008

Snippet

Sponsor: CANbridge Life Sciences Ltd. | Conditions: GBM | Phase 2 | Status: UNKNOWN